C4 Therapeutics, Inc. — Director's Dealing 2021

Aug 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-08-03

Reporting Person: Fisher Stewart (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-03	Common Stock	S	17057	$45.0145	Disposed	22744	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.